

AWG Wastewater Monitoring Program Report No. A2

Summary Report

Constituents of Emerging Concern: South Lake Tahoe Wastewater Effluent Monitoring

Alpine County, CA

April 2018 – October 2021

Report No. A2

Alpine Watershed Group Executive Director: Kimra McAfee

Alpine Watershed Group P.O. Box 296 Markleeville, CA 96120 (530) 694-2327

Study Timetable:

Initiation Date: December 5, 2017 Sampling Start Date: April 23, 2018 Sampling End Date: October 11, 2021 Analysis End Date: November 3, 2021 Report Date: April 18, 2022



Table of Contents:										
Abstract	Page 3									
Executive Summary	Page 3									
Overview	Page 3									
Site Description	Page 4									
Field Sampling Methods and Quality Control	Page 5									
CEC Laboratory Assessment	Page 5									
Laboratory Quality Control	Page 5									
Results Summary and Discussion	Page 6									
Acknowledgements	Page 7									
References	Page 8									
Figure 1 — Sampling Locations	Page 9									
Appendix A: Project Protocol										
Appendix B: PPCP Sample Collection Protocols from Eurofins Eaton Analytical										
Appendix C: Table 1 — Monitored Priority CECs	Page 18									



Abstract:

Pharmaceuticals and personal care products (PPCPs) along with various constituents of emerging concern (CECs) were evaluated in treated effluent from the South Tahoe Public Utility District (STPUD) wastewater treatment facility's source at South Lake Tahoe, CA, and at three sampling locations in the Upper Carson River watershed, Alpine County, CA. This four-year seasonal wastewater monitoring program, initiated in the spring of 2018 and continuing through the fall of 2021, was conducted by Alpine Watershed Group to determine the presence or absence of California State Water Resources Control Board (SWRCB) priority PPCP and CEC contaminants. Between 40 and 103 contaminants were individually evaluated per reclaimed wastewater sample over the spring, summer, and fall monitoring seasons using established USEPA multiresidue analytical methods. The combined results from all sampling sites over the four-year timeframe observed from 37% to 68% of the screened CECs above part per trillion analytical detection. Flame retardant chemicals, industrial surfactants, antibiotics, pain reliefanxiety disorder medications, insect repellents, artificial sweeteners, and caffeine (and its associated breakdown metabolites) were consistently the more abundant contaminants observed at the STPUD reclaimed wastewater effluent source and within the Upper Carson River watershed. All measured environmental concentrations (MECs) were compared to a conservatively-derived threshold human toxicological monitor triggering level (MTL) developed by the SWRCB Scientific Advisory Committee from the scientific literature. For those screened contaminants where MLT data was available, only caffeine and associated breakdown metabolites triggered MEC/MTL monitoring trigger quotients (MTQ) greater then unity (i.e., 1) during Year 1 monitoring, signifying seasonal trends for this constituent (and its associated metabolites) should be closely monitored. The combined multiresidue results of the remaining three years of monitoring consistently showed that the majority of screened SWRCB priority CECs from STPUD reclaimed water were either not detected or, if so, constituent concentrations fell below their corresponding MTQs. Based on SWRCB monitoring criteria and number of priority CECs screened in this investigation, STPUD treated effluent should not pose a significant human, ecological, or agricultural risk when this reclaimed water is exclusively used for forage crop irrigation purposes in the Upper Carson River watershed.

Executive Summary:

Overview:

Chemicals of emerging concern (CECs) signify many man-made substances that can be environmentally persistent and often detected in wastewater treatment effluent at very low part per billion (ppb) to part per trillion (pptr) concentrations and typically are not regulated under current environmental laws (Anderson et al., 2010). Even at these extremely low concentrations, many CECs have documented endocrine disruption-bioaccumulation properties and may deleteriously impact survivability of sensitive aquatic organisms and can potentially pose a risk to public health (Fono et al., 2008). Some examples of emerging constituents include industrial products and their intermediates (i.e., *non-stick* perfluorinated alkyl derivatives alkyl phenol surfactants and plasticizers), food additives (i.e., artificial sweeteners), X-ray dyes, flame retardants, and insect repellants to name a few. Pharmaceuticals and personal care products (PPCPs) also fall under this broad CEC category. Pharmaceuticals are generally comprised of prescription, over-the-counter medications and veterinary drugs for preventing/treating human and animal diseases, while personal care products (skin care products, soaps, and disinfectants) are used mainly to improve the quality of daily life. Along with certain CECs, many PPCPs are also inherently



estrogenic (i.e., synthetic human birth control reproductive hormones and various organic ingredients in soaps and body lotions).

Wastewater treatment effluent is often reclaimed for urban landscape irrigation, ground water recharge, and agricultural irrigation uses (Anderson et al., 2010). As such, it becomes essential to understand what can be in the reclaimed water. Furthermore, can detected concentrations of the above constituents pose deleterious impacts on aquatic organisms and environment? With the above in mind, the goal of this four-year monitoring program was to assess the presence/absence, concentrations, yearly trends and possibility of environmental impacts from CECs discharged into the Upper Carson River watershed in Alpine County from South Lake Tahoe Public Utility District (STPUD) reclaimed effluent.

In September 2017, Alpine Watershed Group (AWG) formulated a PPCP Committee project team consisting of Alpine County public health experts and administrators. AWG staff along with the project team input subsequently developed a field sampling-analytical protocol (Project Protocol, Year One for STPUD Contract Commission Testing for Pharmaceuticals and Personal Care Products (PPCPs) and Constituents of Emerging Concern (CECs) 2018; see Appendix A). The site locations, sampling design, constituent selection, analytical procedures, and reporting timelines from this initial Year One protocol were closely followed (with certain improved analytical method modifications) in subsequent seasonal sampling events over the four-year monitoring timeframe and are summarized below. When lab analyses shifted from Weck Labs to Eurofins Eaton Analytical (EEA) as described below, sample collection protocols were updated to adhere to EEA PPCP Sample Collection Protocols (see Appendix B).

Site Description:

Starting at the STPUD treatment facility, the treated water is pumped 1,235 feet to the Luther Pass summit and then gravity fed through a 27-mile pipeline (referred to as the C-line) to a drainage wetland before being received at Lower Harvey Place Reservoir located in the Upper Carson River watershed of Alpine County (see Figure 1). This reservoir receives STPUD reclaimed water starting mid-October to the beginning of April (Vance and Loden, 2018). The reclaimed water that is held within Harvey Place Reservoir is for forage crop irrigation purposes.

Over the four-year monitoring timeframe, reclaimed water was seasonally sampled by AWG staff at four site locations with one at the STPUD wastewater source, one at the C-line terminus location, one within Harvey Place Reservoir, and the forth location at a lower ditch location where reclaimed water is pumped out of the reservoir for forage crop irrigation purposes (see Figure 1). A more complete site description with mapping coordinates at the source (Site A: STPUD Final Effluent), C-line terminus location (Site B: C-line), within reservoir (Site C: Harvey Place Reservoir), and ditch irrigation pumping location (Site D: Diamond Valley Ditch) can be found in the study protocol, Appendix A. Seasonal effluent monitoring at these four sampling sites was performed consistently over the entire four-year monitoring timeframe with field sampling taking place during the months of April, July, and October. These months were selected to coincide with seasonality of weather, intensity of tourism in South Lake Tahoe (i.e., July 4th holiday), and scheduled reservoir effluent transfer times.



Field Sampling Methods and Quality Control:

The reclaimed water was sampled into either 40ml or 1L amber glass bottles then stored in coolers with ice by AWG staff. Coolers were then shipped 2-day delivery with chain of custody information to the analytical laboratory. In 2018, 2019, and 2021 six total effluent samples/year were respectively taken with three in April at Sites A, B, and C, one in July at Site D, and two in October at sites A and D (see Appendix A, Table 3). In 2020, single sampling was again conducted at sites A, B, and C. However, duplicate sampling was performed at Site D in July and at Site A in October. These 2020 July and October duplicate quality control samples were taken to assess field sampling and analytical laboratory precision/reliability. A duplicate sampling of Site A was also taken in April 2018 and separately analyzed by both Weck Labs and Eurofins Eaton Analytical (EEA) for comparative purposes.

CEC Laboratory Assessments:

Two analytical laboratories were employed by AWG for generating CEC/PPCP residue data. In April and July 2018, Weck Labs in City of Industry, CA, provided sample bottles and performed multiresidue determinations for 39 California State Water Resources Control Board (SWRCB) priority CECs and one urea herbicide used for reservoir and stream bank sterilization (see Table 1 of Appendix A). Starting in October 2018, Eurofins Eaton Analytical (EEA), of Monrovia, CA, provided sampling bottles and conducted SWRCB priority residue determinations for over 103 wastewater constituents through October 2021. Refer to Appendix C for a complete description of priority CECs that were evaluated over the four-year study timeframe.

Laboratory Quality Control:

EEA refrigerated on arrival and extracted/analyzed AWG effluent samples within stated holding times. Analyte quality control recovery information for each assayed priority contaminant was provided, and for the vast majority of analyses was within acceptable EPA 1694 multiresidue method recovery (i.e. 60-140%) and relative percent difference (RPD) precision ranges. When high concentration compounds fell out of instrument linearity range, the samples was appropriately diluted and reanalyzed. Any measured environmental contaminant falling outside acceptable quality control (QC) criteria was highlighted.

Weck Labs performed residue extractions within stated holding times and subsequently performed using EPA 1694M multiresidue methods for 30 CECs, method ASTM D7065 for 8 alkyl phenols, EPA Method 532M for the urea herbicide diuron, and a laboratory-specific method for iohexol, an x-ray imaging dye. Many of the evaluated wastewater residues exceeded the instrument linear calibration range. These effluent samples were not diluted-reanalyzed and therefore could not be precisely quantitated. Weck Labs qualified these residues as semi-quantitative estimates. Moreover, sample matrix interferences for four of five screened hormones appreciably raised the minimum reporting limit rendering these estrogenic substances to not be accurately determined at low concentrations. This qualified data for 17 of the 40 screened contaminants impacted the degree of confidence in estimation but did not mean the data was not reportable. On April 23, 2018, wastewater effluent was sampled at Site A by EEA who was contracted by STPUD. The EEA results were made available by STPUD for comparison to the Site A April 23, 2018, sampling event conducted by AWG staff. The reported residue concentrations from the two laboratories were found to be comparable. The general similarity in results increased confidence in the Weck generated residue data and has therefore been included in this summary report.

Results Summary and Discussion:

The results from analytical reports provided by EEA and Weck laboratories were compiled into a single four-year CEC summary table (see Appendix C). This table provides a description of each CEC evaluated and residues that were (or were not) detected/quantitated over the four-year seasonal monitoring timeframe.

The consistency in CECs evaluated and seasonal field sampling times provided a means to directly compare on a year-to-year basis constituent concentrations and observe if there were any evident seasonal data trends. From Appendix C, on a year-by year basis, the sugar substitutes, acesulfame-K and sucralose were consistently reported to be most abundant and sometimes observed at concentrations greater than 10 parts per billion (ppb) (i.e., greater than 10,000 nanograms per liter (ng/L). Sugar substitutes are also reported to be at more abundant concentrations in many reclaimed municipal wastewater facilities throughout California and the US (Drewes et al., 2018). Notably, caffeine and its three major breakdown metabolites were observed at effluent concentrations exceeding 10 ppb (10,000 ng/L) within the Upper Carson River watershed during October 2018 with reported maximum caffeine concentrations of 52 ppb (52,000 ng/L) at the STPUD Site A reclaimed effluent source. These caffeine concentrations are some of the highest ever reported from any reclaimed treatment water within the US (Lim et al., 2017). Surfactants and detergents were another CEC class present throughout each sampling season. Of these substituents, 4-nonylphenol was observed at some seasonal concentrations exceeding 1 ppb (1,000 ng/L). This substance is considered to have weak estrogenic properties. The contrast x-ray agent iohexol was also observed to routinely have high seasonal concentrations greater than 1 ppb.

A number of PPCPs were also routinely observed at seasonal concentrations that sometime exceeded 1 ppb. These include atenol (a beta blocker), atorvastin (a statin medication), gemfibrozil (a lipid regulator), lidocaine (a numbing agent), ibuprofen and naproxen (anti-inflammatory agents), the antibiotics quinolone and sulfamethoxazole, and the antimicrobial disinfectant triclosan. The flame retardant constituents tris (1, 3-dichloroisopropyl) phosphate (TDCPP) and tris (2-chloro-1-methylethyl) phosphate (TCPP) were also reported to be at effluent concentrations exceeding 1 ppb during the monitoring timeframe. These CECs have reported estrogenic activity. Hormones screened in this effluent monitoring program included 17-a-ethynylestradiol, 17-b-estradiol, estradiol, estriol, estrone and testosterone. All were reported to be at or near non-detectable concentrations over the four-year monitoring period.

<u>Assigning Risk</u>: Three factors enter into whether any of the above reported constituents can pose a potential human health or environmental risk. Besides the measured environmental concentration (MEC), its inherent toxicity and human route/duration of exposure(s) have to be accounted before assigning an appropriate CEC predicted no effect concentration (PNEC) and monitoring trigger level (MTL). A conceptual framework for evaluating CECs in wastewater using a MTL approach developed by a scientific advisory panel for the SWRCB was utilized in assessing the human-environmental risk of measured effluent constituents in this study (see Drewes et al., 2018).

The PNEC toxicological threshold is derived from values in the scientific literature. Here, the PNEC signifies the concentration which marks the limit at which the constituent will likely have no human or environmental toxic effect. Second, the route/duration of exposure has to be accounted for. If potable



water is directly ingested, the PNEC will be equal to the MTL. In the case of Alpine County, non-potable reclaimed irrigation water with disinfection is the end use product for forage crop irrigation. As a result, any human exposure should be appreciably less. In 2018, the SWRCB Scientific Advisory Panel recommended deriving MTLs for non-potable reuse by multiplying the potable reuse MTL by a safety factor of 10 to derive the monitoring trigger quotient (MTQ) or MEC/MTL ratio.

For example, the MEC (i.e., measured effluent concentration) for the sugar substitute acesulfame-K, taken at Site A on October 2018 was 28,000 ng/L (see Appendix C). The potable water MTL for this substance is reported at 200,000,000 ng/L (from Drewes et al., 2018).

Therefore, the MEC/MTL times 10X safety factor = 28,000 ng/L / 200,000,000 ng/L x 10

The monitoring trigger quotient (MTQ) = 0.00014 and is very much less than 1. Or in other words, this low toxicity substance, even at high effluent concentrations, should not pose a human health risk. It is important to note that this quotient is conservative and operationally defined using existing human health toxicological information. A MTQ greater than 1.0 does not necessarily represent any immediate threat to public health but does indicate further effluent monitoring for that constituent is warranted (Drewes et al., 2018).

As stated above, in October 2018 caffeine and its associated metabolites (1,7-dimethylxanthine, theobromine and theophylline) were observed in STPUD treated effluent at extremely high concentrations that warrant attention. Caffeine was respectively measured at 52 and 43 ppb at Sites A and D. The 1,7-dimethylxanthine concentrations were 8.1 and 9.8 ppb at Sites A and D. Theobromine concentrations at Sites A and D were respectively 17 and 15 ppb, while theophylline Site A and D concentrations were respectively 12 and 16 ppb. The relatively similar caffeine and proportional metabolite concentration behavior at both A and D sampling sites together with good laboratory QC recovery values provides strength to the reliability of this effluent monitoring data. MTQ risk values for caffeine for site A and D were respectively 14.6 and 12.3, well above unity (1). MLT values were only available for 1,7-dimethylxanthine and were respectively 1.16 and 1.4.

The fall 2018 caffeine effluent data, in and of itself, indicates STPUD should routinely monitor for this constituent and its associated metabolites at Site A on a regular basis. It is, however, important to note that caffeine was not observed in effluent concentrations that exceeded the MTQ after the fall of 2018. The combined multiresidue results for the remainder of the four-year monitoring program consistently showed that the majority of screened SWRCB priority CECs were either not detected or, if detected, these constituent concentrations fell below their corresponding MTQs. Based on the body of monitoring work performed and SWRCB risk criteria, STPUD treated effluent should not pose any significant human, ecological, or agricultural risk when this reclaimed water is exclusively used for forage crop irrigation purposes in the Upper Carson River watershed.

Acknowledgements:

Many AWG staff (past and present) have contributed towards the completion of this four-year program. Many thanks go to Gavin Feiger for his early program development work, Mo Loden for steering the ship and seeing to the project's near completion and success, AmeriCorps Member Marina Vance for project leadership during AWG staff transitions, and Rachel Kieffer and AmeriCorps Member Sierra Riker for



assisting Kimra McAfee in finalizing this Summary Report. The AWG staff also wish to acknowledge PPCP Committee members Dr. Richard Harvey (AWG Board Chair, STPUD Contract Commission Member, and former Alpine County Public Health Officer), Dr. Richard Johnson (Alpine County Public Health Officer), Ron Hames (Alpine County Supervisor), and Dennis Lampson (Alpine County Director of Environmental Health) for providing study oversight and advisement. We wish to also thank Dr. Vincent Hebert (Citizen at Large) for providing his critical review and for drafting this final report.

Funding for this program came from funds provided by South Tahoe Public Utility District to Alpine County for water quality monitoring associated with the District's treated effluent discharge in Alpine County. Alpine County contracted with Alpine Watershed Group to oversee monitoring project design, conduct sampling, and provide basic data analysis and recommendations.

References:

Anderson P, Denslow N, Drewes JE, Olivieri A, Schlenk D, and S Snyder. 2010. Monitoring Strategies for Chemicals of Emerging Concern (CECs) in Recycled Water: Recommendations of a Science Advisory Panel. State Water Resources Control Board. 217 pp.

Drewes JE, Anderson P, Denslow N, Jakubowski W, Olivieri A, Schlenk D, and S Snyder. 2018. Monitoring Strategies for Constituents of Emerging Concern (CECs) in Recycled Water. Recommendations of a Science Advisory Panel convened by the State Water Resources Control Board. SCCWRP Technical Report 1032. 155 pp.

Fono LJ and HS McDonald. 2008. Emerging compounds: A concern for water and wastewater utilities. *Journal AWWA* 100: p 50-57.

Lim FY, Ong SL, and J Hu. 2017. Recent advances in the use of chemical markers for tracing wastewater contamination in aquatic environment. *Water.* 217 9, 143. 26 pp.

Vance M and M Loden. 2018. Pharmaceutical and Personal Care Products Monitoring Project-Year One. Interim report. Report No. 1A. Alpine Watershed Group. 39 pp.



Figure 1. Sampling Locations





AWG Wastewater Monitoring Program Report No. A2

Appendix A Project Protocol





Project Protocol, Year One for STPUD Contract Commission Testing for Pharmaceuticals and Personal Care Products (PPCPs) and Contaminants of Emerging Concern (CECs) 2018

Background

The goal of this monitoring project is to document the presence, concentrations, and trends of Pharmaceuticals and Personal Care Products (PPCPs) and other Contaminants of Emerging Concern (CECs) in wastewater (effluent) discharged into the Upper Carson Watershed in Alpine County by the South Lake Tahoe Public Utility District (STPUD). Effluent is exported 26 miles from South Lake Tahoe to Harvey Place Reservoir in Alpine County. During the first year of water testing, Alpine Watershed Group (AWG) hopes to establish baseline conditions for subsequent monitoring years in relation to CECs and PPCPs within Alpine County.

In September 2017, AWG convened a Project Team which consists of Richard Harvey (AWG Board Member, STPUD Contract Commission Member, and former Alpine County Public Health Officer), Richard Johnson (current Alpine County Public Health Officer), Ron Hames (Alpine County Supervisor), Dennis Lampson (Alpine County Director of Environmental Health), and AWG Staff. The Project Team, with input from Alpine County officials, decided to use Weck Labs from the City of Industry, California, to analyze the samples. The contaminants chosen to test for include: 9 Alkyl Phenols, 5 Hormones, 21 Pharmaceuticals, 1 Urea Pesticide, and 5 Organic Compounds (see Table 1). Weck Labs is certified through the U.S. Department of Defense Environmental Laboratory Accreditation Program (ELAP).

	Diuron/		Pharmaceuticals	Pharmaceuticals	Organic
Alkyl Phenols	linuron	Hormones	(-)	(+)	Compounds
4-Nonylphenol	Diuron	17-a-Ethynylestradiol	Bisphenol A	Acetaminophen	TCEP
4-Octylphenol		17-b-Estradiol	Diclofenac	Amoxicillin	ТСРР
4-tert-Octylphenol		Estrone	Gemfibrozil	Azithromycin	TDCPP
4-tert-Octylphenol diethoxylate		Progesterone	Ibuprofen	Caffeine	Trimethoprim
4-tert-Octylphenol monoethoxylate		Testosterone	lopromide	Carbamazepine	lohexol
Nonylphenol			Naproxen	DEET	
Nonylphenol diethoxylate			Salicylic Acid	Diazepam	
Nonylphenol monoethoxylate			Triclosan	Fluoxetine	
4-Nonylphenol-d4				Meprobamate	
				Methadone	
				Phenytoin	
				Primidone	
				Sulfamethoxazole	

Table 1. Contaminants of Emerging Concern (CEC)



Monitoring Sites

These four sites were chosen based on their relationship and proximity to the C-line and the general distribution of effluent within Harvey Place Reservoir. The C-line is the pipeline that delivers the secondary treated effluent from the STPUD facility in South Lake Tahoe to Alpine County. See Table 2 for monitoring site information and Figure 1 for sampling locations. The Project Team coordinated the monitoring schedule of these locations based on seasonality of weather and tourism in South Lake Tahoe, effluent transfer system design, holding time in Harvey Place Reservoir, and the project budget.

Table 2. Monitoring Site Information

Site			
ID	Site Name	Site Description/Significance	Coordinates
А	STPUD Final Effluent	Located in South Lake Tahoe at the Public Utility District facility, this site is sampled at the valve that connects to the effluent C-line pipe after all treatments are completed.	38.922775, -119.970664
В	C-line	Located at the end of the pipeline in Alpine County, this site is sampled mid-stream from a bridge before it comes into contact with any environmental conditions.	38.758606, -119.797722
С		Located along the shore at the downstream northwest end, this site represents the concentrations of the reservoir.	38.765262 <i>,</i> -119.783764
D		Located at the most upstream end of the ditch where water pumps out of the reservoir, this site is sampled from a bridge at mid- stream and represents concentrations flowing into ranches within Diamond Valley and Alpine County.	38.765470, -119.780575

Figure 1. Sampling Locations





Monitoring Timeline

AWG launched this PPCP and CEC monitoring project in Spring 2018 and will conclude our first year of preliminary data collection in Fall 2018. Ideally, Alpine County will contract AWG again for the next year in hopes of continuing monitoring for contaminants if not for our own analysis but for development of increasing data for an emerging field of water quality and public health.

Specifically, within this first year, AWG has enough funds in the budget for six samples. The sampling bottles sent from Weck Labs have a shelf life of up to six months. With the background information in mind, sampling early April before the pump opens would represent the most concentrated effluent level. Another high priority sample date would be during the week following Independence Day (July 4th) due to the population surge for the holiday. The last sample date would be in October shortly before the irrigation supply is suspended for the season. To maintain consistency, the sampling should be at the same time of day each event (e.g., 9 a.m.).

Table 3. First Year Sampling Date

Sampling Site	April 23 rd	July 9 th	October 10 th
Site A: STPUD Final Effluent	x		х
Site B: C-line	х		
Site C: Harvey Place Reservoir	x		
Site D: Diamond Valley Ditch		X	Х

Monitoring Equipment

Sampling kits will be provided by Weck Labs which will include a cooler with: 2X 1L Amber glass containers containing NaN3 and Ascorbic Acid 2X 1L Amber Glass with H2SO4 2X 40mL VOAs

Return coolers with samples on wet ice and ship 2-day.

Conducting Samples

Standard Operating Procedures (SOP) for field methods include filling the containers up to the neck while not overfilling them and shipping them back on ice. The sampling bottles will be shipped to AWG with preservative in them and returned to Weck Labs. See detailed SOP in AWG's Quality Assurance Project Plan (QAPP).

Excerpt from QAPP:

Field personnel must be thoroughly trained

- in the proper use of sample collection gear,
- *in distinguishing acceptable versus unacceptable samples in accordance with pre-established criteria,*



• to recognize and avoid potential sources of sample contamination.

Sampling equipment and utensils that come in direct contact with the sample should be made of noncontaminating materials and should be thoroughly cleaned between sampling stations. Sample storage containers should be of the recommended type and must be free of contaminants. Conditions for sample collection, preservation, and holding times should be followed, and relevant field observations should be recorded. On the day of sampling, field personnel should avoid contact with or consumption of products that contain the target analytes. This may include soaps, detergents, fragrances, sunscreen, and pharmaceuticals. Storage containers with Teflon should not be used to store samples that are slated for analysis of perfluorinated compounds (PFCs).

Reporting

After sample analysis has been sent to AWG in the form of a PDF document, AWG will create a summary of the data for the STPUD Contract Commission, watershed stakeholders, and the general public. The data will be input into the CEDEN database for the Statewide CEC Monitoring interactive map.

Project Budget

Alpine County agreed in 1967 to take treated sewage from the STPUD "assuring the protection of the health and welfare of the residents of the County and Agency..." Alpine County has the legal right to independently monitor for any possible contaminants in the treated secondary effluent received from STPUD. Alpine County can receive \$15,000/year from the STPUD to monitor for contaminants that may have negative effects on the environment and on human health. Alpine County has not done independent monitoring since 2009. There has been increasing concern that the wastewater received from the STPUD may contain hormones and personal care products. At the August 1, 2017, STPUD Contract Commission meeting, a decision was made to monitor the STPUD effluent for CECs. Further, the Commission agreed to contract Alpine Watershed Group (AWG) to conduct the monitoring.

			Ambient
Location	Date	Time	Temperature*
Site A: STPUD Final Effluent	4.23.18	8:10 a.m.	
Site B: C-line	4.23.18	9:30 a.m.	
Site C: Harvey Place Reservoir	4.23.18	10:00 a.m.	
Site D: Diamond Ditch	7.09.18	9:30 a.m.	
Site A: STPUD Final Effluent	10.10.18	TBD	
Site D: Diamond Ditch	10.10.18	TBD	

Sampling Collections:

*Collect ambient temperature day of from STPUD weather station at <u>https://cimis.water.ca.gov/WSNReportCriteria.aspx#</u> Weather Station Number 246.

For first two sampling events, used weatherunderground.com



Appendix B PPCP Sample Collection Protocols from Eurofins Eaton Analytical

 	eurofins Eaton Analytical	PPCP Sample Collection Prot	ocols	Sampling Instruction No. 33 Revision Date: 10/22/13 Page 1 of 2
1.	SAMPLING.	ECEIPT OF SAMPLE KIT AND ADD FROZEN O OTHER AVAILABLE BAGGED WET ICE IN LE COLLECTION.		
2.	2 x 40 ml amber vial 2 x 500 ml or 1L am Upon special request, our lab m	mple kit from our lab as follows: s with preservative are provided for the s ber glass bottles with preservative are pr ight include one or both additional kits below at blank (EB): 1 container filled with DI water a	ovide for large :	volume tests
		ontains toxic preservatives to prevent biologi es vary, depending upon the matrix being san	-	
3.	 below when sampling for PF a) Put on powderless nitrile change in activity to avoid b) Avoid touching or even b c) Avoid direct contact betwee equipment. Clothing is a d) On the day of sampling a with or consumption of t Wastewater and Persona Soaps and deterg DEET (active ingree Fragrances (cologe Caffeine or Sweet 	gloves at all times, during sampling and d potential glove contamination. reathing into the samples and/or equipm veen yourself (including clothing) and the source of detergents, fragrances, and fire ctivities, avoid contact with or consumpt hese products is unavoidable, the collect al Care or Pharmaceutical Product compo ents, including antibacterial cleansers edient in most insect repellents) ne, aftershave, perfume) eners (coffee, tea, colas) s, medications, and hormonal substances	processing. Ch nent. e sample, samp e retardants ion of the prod ion of field blan unds: • Human • Veterina • Tobacco • Sunscree	ange to clean gloves with each ling device, and processing lucts listed below. Where contact nks is strongly recommended. antibiotics ary antibiotics o en
4.	Field Blank (FB): Transfer the DI wate Cap both containers Equipment Blank(EB): Pour the DI water pi device) and transfer	onal blank samples, please follow the spe er provided with your sample kit into the and return them to the laboratory. rovided with your sample kit into the equ it into the EB sample bottle(s). nd return them to the laboratory.	FB sample bott	tle.
5.	Use indelible ink to clearly id - Client Name - Sample ID - Source of sample, if	- Date an	required, if not d Time of collect	already on label
6.		, screen and/or hose attachments. t the water of the sample source run at fa	ast flow for app	proximately 5 minutes.

Eaton Analytical	PPCP Sample Collection Protocols	Sampling Instruction No. 33 Revision Date: 10/22/13 Page 2 of 2
------------------	----------------------------------	---

- c) Slow water flow to thickness of a pencil (to minimize splashing) and fill sample bottles.
- 7. Fill sample bottles to <u>the base of the neck</u>. Make sure the mouth of the bottle does not come in contact with anything other than the sample water. **DO NOT RINSE OUT PRESERVATIVE.**
- 8. Cap and invert the bottles at least 5 times to mix the sample and preservative.
- 9. Use indelible ink to clearly identify the sample bottles with the information listed below.
 - Client Name

- Analysis required, if not already on label

- Sample ID

- Date and Time of collection
- Source of sample, if not already on label
- Preservative used, if not already on label
- 10. Store at 1-4°C but above the freezing point of water for a minimum of 2 hours until transported to the lab. Note that some test suites do not require chilling. Check with your analytical service manager for details.
- 11. If sampling **NOT** from a faucet, please follow the following instruction to collect and process the sample(s):
 - a) Select sampling and processing equipment made of fluorocarbon polymers, glass, aluminum, or stainless steel. <u>Avoid</u> equipment made of Tygon, polyethylene, or other plastics.
 - b) Clean equipment thoroughly before use.
 - c) Use non-antibacterial detergents.
 - d) Take extra care to ensure that equipment is copiously rinsed with deionized (DI) water after the detergent wash. (Detergents are a source of interference in the analysis of pharmaceutical compounds and may include a target analyte (triclosan) of the method.)
 - e) Follow the DI water rinse with a methanol rinse. Collect the used methanol solution into an appropriate container for disposal.
 - f) **DO NOT** clean or field-rinse the sample bottles from the laboratory.
 - g) And follow steps 7-10 above.

SAMPLE SHIPPING AND STORAGE

- 1. If shipping samples on the same day of sampling, chill samples until ≤6°C by exchanging the ice used during sampling with available sealed bags of fresh frozen ice or frozen gelpaks.
- 2. <u>Pack chilled samples</u> in a cooler with <u>FROZEN</u> gelpaks or sealed bags of WET ICE.
- Complete the Chain of Custody during sample collection. Place Kit Order and completed Chain of Custody in a ziplock bag in the cooler on top of packing material. The following information is required on the completed Chain of Custody.
 Collector's name & signature
 Date and time of collection

0	
- Client Name	-Comments about the sample, if applicable
- Sample site	-Sample type

- Ship via overnight service such as FEDEX, UPS, or DHL, etc. Maintain an environment at ≤6°C but above the freezing point of water during transit. It is recommended that samples arrive within 48 hours of sampling, with no more than 40 hours for transit.
- 5. If samples are received on the same day as collection, temperature may be $>10^{\circ}$ C with evidence of cooling.
- 6. Maximum HOLDING TIME FOR SAMPLES varies by test list, but it is generally **30 days** from time of collection.
- Alternatively, cool the samples down by placing them <u>overnight</u> in a cooler with frozen refrigerant packs or water ice, or in a refrigerator (store chilled for at least 12 hours before packing for shipment). Maintain the cold samples until repacked in the cooler for shipment to the lab.



Appendix C Table 1 — Monitored Priority CECs

High detections	Very high detections				Results (ng/L) NA: Not Available, ND: Not Detected																								
> 1,000ng/L	>10,000ng/L	August 2017		Apri	l 2018		July 2018	Octob	er 2018		April 2019		July 2019		er 2019		April 2020		July	2020		October 202	0		April 2021		July 2021	Octobe	er 2021
		EEA	Weck	EEA	Weck	Weck	Weck	EEA	EEA	EEA	EEA	EEA	EEA	EEA	EEA	EEA	EEA	EEA	EEA	Site D	EEA	Site A	EEA	EEA	EEA	EEA	EEA	EEA	EEA
Compounds Analyzed	Descriptions/Functions	Site A	Site A	Site A	Site B	Site C	Site D	Site A	Site D	Site A	Site B	Site C	Site D	Site A	Site D	Site A	Site B	Site C	Site D	Duplicate	Site A	Duplicate	Site D	Site A	Site B	Site C	Site D	Site A72	Site D5
1,7-Dimethylxanthine 17-a-Ethynylestradiol	caffeine metabolite reproductive hormone, synthetic hormone in	34	NA	396	NA	NA	NA	8100	9800	84	170	160	350	52	350	390	470	40	350	350	150	150	280	240	220	340	280	76	91
	pharmaceuticals	NA	ND	ND	ND	ND	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	120	NA	NA
17-b-Estradiol	reproductive hormone, synthetic hormone in pharmaceuticals, natural hormone/steroid	NA	ND	ND	ND	ND	12	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
1H-Benzotriazole	poorly degraded-water soluble corrosion inhibitor	NA	NA	NA	NA	NA	NA	NA	NA	810	200	420	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
2,4-D 4-n-Octylphenol diethoxylate	plant growth hormone mimic, herbicide detergent, surfactant	ND NA	NA NA	5.05 NA	NA NA	NA NA	NA NA	3400 ND	970 ND	ND ND	ND ND	46 ND	41 NA	42 NA	620 NA	2300 NA	260 NA	380 NA	260 NA	260 NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	NA NA	34 NA	92 NA
4-n-Octylphenol monoethoxylate	detergent, surfactant	NA	NA	NA	NA	NA	NA	ND	ND	ND	ND	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
4-Nonylphenol 4-Octylphenol	detergent, surfactant - weak estrogenic effects detergent, surfactant	ND NA	ND ND	6840 NA	ND ND	ND ND	ND ND	1400 NA	2300 NA	1300 NA	1400 NA	ND NA	ND NA	1600 220	400 46	2600 NA	2900 NA	1900 NA	1200 NA	1600 NA	6200 NA	7500 NA	ND NA	5100 NA	NA	ND	310 NA	5400 NA	1900 NA
4-tert Octylphenol diethoxylate	detergent, surfactant	NA	ND	NA	ND	ND	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	87	76	NA	NA	NA	NA	NA	NA	NA	NA	NA
4-tert-Octylphenol 4-tert-octylphenol monoethoxylate	detergent, surfactant detergent, surfactant	ND NA	370 ND	ND NA	170 ND	ND ND	ND ND	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	NA	NA	380 NA	380 NA	27 NA	NA	NA	520 NA	500 NA	170 NA	310	240	ND	37 NA	230 NA	57 NA
Acesulfame-K	sugar substitute	ND	NA	8310	NA	NA	NA	28000	23000	17000	17000	15000	12000	28000	20000	21000	20000	24000	15000	16000	16000	16000	10000	NA 33000	NA 26000	NA ND	3000	4800	1900
Acetaminophen Albuterol	pharmaceutical - fever reducer bronchodilator, asthma treatment	15.6 78	27 NA	159 20.7	29 NA	ND NA	ND NA	ND ND	ND 8	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND 16	ND 4.7	ND ND	ND ND	ND 5.1	ND 8.6	ND 9	ND 7.6	ND 12	ND 4.7	ND 3.8	ND 7.4	6.4 7.9
Amoxicillin	antibiotic	122	840	399	30	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Andorostenedione Atenolol	androgen steroid hormone beta-blocker, treat high blood pressure	ND ND	NA NA	ND 1030	NA NA	NA NA	NA NA	ND 1000	ND 450	ND 640	ND 520	ND 51	ND 100	3.8 790	4.4	ND 700	ND 700	ND 93	8.7 90	7.7	ND 640	ND 680	ND 190	ND 550	ND 530	ND 76	5.9 86	44 290	36 83
Atorvastatin	statin, lowers level of cholesterol	NA	NA	4920	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Atrazine Azithromycin	herbicide antibiotic	ND NA	NA 150	ND	NA 160	NA ND	NA ND	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND NA	ND	ND NA	ND	ND NA	ND NA	ND NA
Bendroflumethiazide	thiazide diuretic, hypertension drug	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Bezafibrate	lipid-lowering agent to treat hyperlipidemia	ND	NA	ND	NA	NA	NA	55	51	27	34	26	15	13	26	17	23	8	6.7	7.5	6.2	6.9	9.4	65	71	12	5.4	12	13
Bisphenol A Bromacil	plasticizer - added to plastics to improve flexibility	NA ND	87 NA	79.8 ND	82 NA	ND NA	12 NA	ND ND	23 ND	77 ND	59 ND	ND ND	ND ND	90 ND	14 ND	60 ND	72 ND	ND ND	12 ND	12 ND	130 ND	150 ND	21 ND	81 ND	62 ND	ND ND	11 ND	100 ND	36 ND
Butalbital	barbiturate	ND	NA	ND	NA	NA	NA	ND	ND	8.1	8.9	ND	14	12	15	23	28	23	32	32	24	25	26	27	ND	ND	25	14	20
Butylparaben	paraben, preservative	ND	NA	ND	NA	NA	NA	ND	ND	ND 150	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND 250	ND	ND	ND	ND	ND	ND	ND	ND
Caffeine Carbadox	stimulant antibiotic	66.7 ND	68 NA	175 ND	170 NA	5400 NA	1400 NA	52000 ND	43000 ND	150 ND	250 ND	410 ND	1300 ND	26 ND	810 ND	1000 ND	1300 ND	120 ND	1200 ND	1000 ND	250 ND	230 ND	880 ND	680 ND	390 ND	500 ND	600 ND	190 2.4	110 ND
Carbamazepine	pharmaceutical - antiepileptic	137	130	204	130	130	100	170	170	120	100	110	100	190	290	180	180	170	120	120	170	160	140	180	160	140	120	150	180
Carisoprodol Chloramphenicol	muscle relaxant antibiotic	9.78 ND	NA	11.3 ND	NA	NA NA	NA	32 ND	36 ND	6.8 ND	8.4 ND	18 ND	29 ND	11 ND	16 ND	22 ND	42 ND	28 ND	37 ND	35 ND	18 ND	21 ND	33 ND	53 ND	21 ND	41 ND	46 ND	18 ND	35 ND
Chloridazon	herbicide	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Chlortoluron Cimetidine	herbicide antihistamine	ND ND	NA	ND ND	NA	NA	NA	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND 7.4	ND ND	ND ND	ND ND	ND 9.5	ND 7.1	ND ND	ND ND	ND 21	ND ND	ND ND	ND ND	ND 8.4	ND ND	ND ND
Clofibric acid	herbicide	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Cotinine Cvanazine	nicotine metabolite pesticide	ND ND	NA NA	ND ND	NA NA	NA	NA NA	360 ND	360 ND	370 ND	330 ND	100 ND	98 ND	2100 NA	450 NA	360 ND	250 ND	55 ND	90 NA	100 NA	95 NA	140 NA	64 NA	52 NA	62 NA	NA 65	64 NA	39 NA	25 NA
Diaminochlorotriazine (DACT)	herbicide	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	NA	ND	ND	ND	ND
Diethanolamine (DEA)	cosmetic ingredient	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	20	ND	ND	ND	ND	ND	ND	ND	ND	ND	14	19	13	12	5	11
N,N-Diethyl-meta-toluamide (DEET)	insect repellent antihypertensive drug metabolite	36.4 ND	600 NA	579 ND	780 NA	460 NA	140 NA	580 ND	410 ND	350 ND	310 ND	220 ND	250 ND	300 1.8	240 2.6	650 ND	680 ND	560 ND	530 ND	510 ND	260 ND	240 ND	310 ND	210 1.9	190	290 ND	350 ND	ND ND	ND ND
Diisopropylatrazine (DIA)	triazine herbicide degradation product	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Diazepam	treat anxiety, alcohol withdrawal, seizures (valium)	ND	2.5	ND	2.2	2.9	2.2	ND	ND	ND	ND	ND	ND	7.9	3.5	ND	ND	ND	ND	ND	ND	ND	ND	3.4	3.2	2.1 ND	2.8	2.8	2.7
Diclofenac Dilantin	nonsteroidal anti-inflammatory drug (NSAID) anticonvulsant, treat seizures	ND ND	46 NA	109 69.6	84 NA	ND NA	ND NA	8.1 50	17 78	100 ND	73 ND	ND 20	ND 31	240 42	27 50	260 24	180 20	ND 21	55 24	40 24	160 40	180 35	25 39	36	39	43	28 32	690 29	57 32
Diltiazem	calcium channel blocker, antihypertensive drug	ND	NA	113	NA	NA	NA	200	35	160	130	9.9	7.1	290	23	84	140	9	3.9	4	120	120	12	190	230	21	6.7	220	30
Diuron Erythromycin	herbicide gut motility stimulator, antibiotic	448 ND	ND NA	102 57.9	ND NA	ND NA	ND NA	170 23	180 41	68 49	39 23	26 ND	58 ND	210 17	170 12	140 ND	110 ND	53 ND	75 10	73	390 ND	410	350 ND	280 83	190 100	84 19	120 300	110 63	140 77
Estradiol	hormone	ND	NA	ND	NA	NA	NA	ND	ND	6.1	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Estriol Estrone	hormone hormone	ND 46.2	NA ND	ND 83.2	NA 46	NA ND	NA ND	ND ND	ND 74	13 44	11 35	ND 7.8	ND ND	ND 23	ND 11	ND 62	ND 57	ND ND	ND 9.3	ND 9.2	ND 60	ND 64	ND 58	ND 39	ND 40	ND ND	ND ND	ND 130	ND 14
Ethinyl Estradiol - 17 alpha	estrogen steroid hormone	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Ethylparaben Flumeqine	paraben, preservative antibiotic	ND ND	NA	ND ND	NA	NA	NA NA	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND
Fluoxetine	antidepressant	ND	19	41.2	23	NA 1	2.7	48	9.7	28	29	ND ND	ND	26	4.7	ND 89	86	8.3	ND ND	ND	29	34	ND	88	82	ND	ND	76	ND
Gemfibrozil	lipid regulator	95.6	66	52.7	70	330	290	1100	930	620	510	500	530	830	660	960	880	380	370	400	610	580	450	850	NA	ND	430	1000	1000
lbuprofen Iohexol	anti-inflammatory contrast agent for x-ray	907 50.3	100 86	ND 112	180 94	690 430	65 420	ND 2360	290 1730	51 260	68 190	220 1500	ND 1100	260 4100	140 2700	5500 550	4000 830	560 780	70 1200	ND 1100	160 6600	200 7600	350 2400	1400 430	1700 450	ND 98	98 2400	180 310	230 2800
Iopromide	non-ionic x-ray contrast agent	ND	ND	6.63	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	4.8	ND	ND
Isobutylparaben Isoproturon	paraben, preservative pesticide	ND ND	NA	ND NA	NA	NA NA	NA NA	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND
Ketoprofen	anti-inflammatory drug	10.3	NA	33.9	NA	NA	NA	ND	ND	9.2	ND	ND	ND	7	ND	ND	ND	ND	ND	ND	ND	ND	ND	14	10	ND	3.1	5.8	5.4
Ketorolac	anti-inflammatory drug	ND	NA	12.7	NA	NA	NA	ND	ND	6.4	ND	ND	ND	11	9.3	ND	4.7	ND	ND	ND	9	8.4	6.3	17	14	ND	3	18	18
Lidocaine	numbing agent antibiotic	526 842	NA	97.6 ND	NA	NA	NA	580 ND	400 ND	560 ND	350	180	150 ND	780	470 ND	460 ND	630 ND	350 ND	240 ND	250	1000	1100	750	1200	1000 ND	480 ND	140 ND	ND ND	ND ND
Lincomycin Linuron	antibiotic herbicide	842 ND	NA NA	ND ND	NA NA	NA NA	NA NA	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND	ND ND	ND ND	ND ND	ND ND
Lopressor	beta blocker/heart medication	239	NA	190	NA	NA	NA	330	250	230	170	68	84	290	110	140	120	77	46	58	360	320	260	590	600	330	220	260	200
Meclofenamic Acid Meprobamate	Non-steroidal anti-inflammatory agent (NSAID) anxiolytic drug, treats tension and anxiety (sedative)	135 131	NA 640	192 71.5	NA 420	NA 470	NA 170	ND 140	ND 100	ND 51	ND 58	ND 71	ND 140	ND 360	ND 400	ND 240	ND 260	ND 97	ND 250	ND 230	ND 150	ND 150	ND 170	ND	ND 150	ND 220	ND 410	ND 90	ND 160
Metazachlor	herbicide	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	140 ND	150 ND	220 ND	ND	ND	ND
Metformin	anti-diabetic	214	NA	3950	NA	NA	NA	150	100	NA	NA	NA	21	8.2	7.1	ND	68	ND	21	18	18	28	5.5	18	38	39	44	2.5	6

Appendix C Table 1. Monitored Priority CECs

High detections	Very high detections											Results	(ng/L) №	: Not Availab	ole, ND: Not D	etected													
> 1,000ng/L	>10,000ng/L	August 2017		Apr	il 2018		July 2018	Octob	er 2018		April 2019		July 2019	Octobe	er 2019		April 2020		July 2	020		October 2020)		April 2021		July 2021	October	r 2021
Compounds Analyzed	Descriptions/Functions	EEA Site A	Weck Site A	EEA Site A	Weck Site B	Weck Site C	Weck Site D	EEA Site A	EEA Site D	EEA Site A	EEA Site B	EEA Site C	EEA Site D	EEA Site A	EEA Site D	EEA Site A	EEA Site B	EEA Site C	EEA Site D	Site D Duplicate	EEA Site A	Site A Duplicate	EEA Site D	EEA Site A	EEA Site B	EEA Site C	EEA Site D	EEA Site A72	EEA Site D5
Methadone	opioid, treat pain	12.9	32	45.2	31	5.1	4	ND	ND	NA	NA	NA	ND	32	14	20	22	4.9	4.8	3.9	31	29	16	6.5	NA	ND	15	37	12
Methylparaben Metolachlor	paraben, preservative herbicide	ND ND	NA NA	ND ND	NA	NA	NA	ND ND	ND ND	ND NA	ND NA	ND NA	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	11 ND	ND ND	ND ND
Morphine	narcotic	503	NA	167	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Naproxen	anti-inflammatory	ND	1100	2900	990	400	150	ND	800	460	330	150	55	860	600	7700	4600	730	540	520	490	520	1800	1300	NA	ND	210	44	340
Nifedipine	calcium channel blocker, antihypertensive drug	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Nonylphenol	non-ionic detergent metabolite	NA	1700	NA	1500	630	1300	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Nonylphenol diethoxylate	surfactant, detergent	269	620	370	ND	550	ND	ND	ND	ND	ND	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Nonylphenol Monoethoxylate	surfactant, detergent	ND	1600	1680	570	580	ND	ND	ND	ND	ND	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Norethisterone OUST (Sulfometuron, methyl)	synthetic birth control hormone herbicide	ND ND	NA NA	ND ND	NA	NA	NA	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND 3.3	ND 4.1	ND 56	ND 29	ND 28	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND
Osolinic acid	antibiotic	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	4.1 ND	ND	ND ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Oxybenzone	aromatic ketone, sunscreen agent, PCP	12.5	NA	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Pentoxifylline	vasodilator and anti-inflammatory	ND	NA	6.85	NA	NA	NA	13	7.6	ND	ND	ND	ND	15	4.8	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	4.5	33	8.9
Phenazone	analgesic, anti-inflammatory	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Phenytoin	anticonvulsant, treat seizures	NA	120	NA	33	56	54	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Praziquantel	antiparasite, tapeworm	ND	NA	ND	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Primidone	anticonvulsant, treat seizures	51.9	36	ND	24	76	41	86	74	44	38	37	45	74	120	60	63	54	61	67	82	96	120	46	94	95	57	21	26
Progesterone	sex hormone in ovaries, natural hormone/steroid	ND	ND	ND	1.1	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Propazine	herbicide	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND NA	ND NA	ND	ND	ND	ND NA	ND	ND	ND NA	ND NA	ND	ND NA	ND NA	ND	ND	ND NA	ND	2.9
propranolol Propylparaben	beta blocker/heart medication paraben, preservative	5.61 ND	NA NA	19.7 NA	NA	NA	NA	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA ND	NA E	NA 46	NA ND	NA ND	NA ND	NA 37
Quinoline	antibiotic/antiseptic	63	NA	6601	NA	NA	NA	89	17	ND	ND	ND	26	ND	ND	37	60	ND	25	29	60	50	18	26	34	50	52	14	3.5
Salicylic Acid	Natural product, major component in aspirin	277	63	ND	100	ND	ND	ND	ND	NA	NA	NA	ND	ND	84	330	240	650	ND	ND	430	410	ND	ND	ND	ND	34	36	ND
Simazine	herbicide	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Sucralose	artificial sweetener	103000	NA	33100	NA	NA	NA	32000	31000	20000	22000	22000	23000	45000	40000	39000	34000	30000	35000	36000	56000	60000	46000	42000	NA	860	28000	50000	51000
Sulfachloropyridazine	antibiotic	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	4	ND	2.6
Sulfadiazine	antibiotic	ND	NA	ND	NA	NA	NA	ND	ND	55	49	21	ND	6.4	22	ND	ND	23	ND	ND	ND	ND	ND	51	59	6.3	27	21	9.5
Sulfadimethoxine	antibiotic	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Sulfamerazine	antibiotic	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	10	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	71	82	23	ND	41	29
Sulfamethazine Sulfamethizole	antibiotic antibiotic	ND ND	NA NA	ND ND	NA	NA	NA NA	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND
Sulfamethoxazole	antibiotic	1590	1500	1390	1100	730	520	920	670	480	470	500	440	920	770	670	790	580	500	490	600	600	560	1000	1000	610	680	950	480
Sulfathiazole	antibiotic	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Tris (2-chloroethyl) phosphate (TCEP)	flame retardant	84.3	140	344	87	70	72	170	160	450	330	160	230	260	400	70	290	240	150	150	260	210	270	300	470	320	450	270	220
Tris (2-chloro-1-methylethyl) phosphate (TCPP)	flame retardant	ND	2500	1170	2300	1800	1800	1400	1100	780	720	680	480	500	510	770	900	710	900	880	850	970	880	1100	1200	1100	860	830	930
Tris (1,3-dichloroisopropyl)	flame retardant	911	300	912	360	300	830	220	180	ND	ND	ND	270	330	300	170	240	110	340	290	360	330	270				690	410	1000
phosphate (TDCPP) Testosterone	reproductive hormone, natural hormone/steroid										1													320	330	310			
		8.81	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	30	5.2	7.8
Theobromine	caffeine metabolite caffeine metabolite	44.8 238	NA NA	610 264	NA NA	NA NA	NA NA	17000 12000	15000 16000	99 130	160 280	40 330	350 630	ND 64	ND 420	370 710	500 780	ND 81	250 530	190 440	ND 160	ND 180	ND 360	330 280	300 220	410 700	96 740	510 280	330 310
Theophylline Thiabendazole	fungicide	238 ND	NA	6,29	NA	NA	NA	22	16000	130 ND	280 ND	330 ND	630 ND	2.7	420	710	780	81 ND	4.5	440	160 ND	180 ND	360 ND	280	33	10	740 11	280	20
Triclocarban	antibiotic	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	4.0 ND	ND	ND	ND	15	48	ND	ND	18	56
Triclosan	antimicrobial disinfectant	1490	130	242	95	11	5.2	ND	32	160	130	ND	ND	150	13	340	140	ND	ND	ND	ND	ND	ND	44	41	ND	11	43	31
Trimethoprim	antibiotic	632	400	474	520	180	110	210	220	210	210	150	91	250	240	62	97	95	88	93	140	140	140	300	390	150	89	290	210
Venlafaxine	antidepressant	NA	NA	NA	NA	NA	NA	NA	NA	150	130	81	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Warfarin	Blood thinner	ND	NA	ND	NA	NA	NA	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Qty N		14	78	-	2 78	3 78	78	3 15		17			19	20	20	19	9 19	19	20	20	20	20	20	20	20	20	20	20	20
Qty NI Total NA/NI	D Qty ND D Total NA/ND	67	11	ž 5	/ 10	18	18	3 68 5 83	02	60) 63 7 80	0.	67	50	50	57	54	+ 62	55	56	58	5 57	60	47	47	65	44	45	44
Total NA/NI Total Compounds Detecte	D Total NA/ND d Total Compounds Detected	81	. 89	-	9 88	96	96	2 35		41	00		20 20	/0	/0	42	2 49	81	/5	/6	2 /8 40	3 // 0 41	20	J 6/	45	85	64 c 4	53	54
Total Compounds Measure	rotal Compounds Detected Total Compounds Measured	3/	40	-	5		22 AC	2 35		101	101		32	48	48	42	90		43	42	40	41	3 9	S 08	92	33	94	98	98
% Compounds Detecte	% Compounds Detected	35.58%	10			-0	55.00%	33.98%		40.59%			32.32%	48.98%	48.98%	42.42%	, 55	55	43.88%	42.86%	40.82%	41.84%	38.789	5 52.04%	52	33.67%	55.10%	54.08%	55.10%
Average of Compound	k Compounds Detetted		/2.50%			55.00%				40.59%		31.08%				42.42%		o 37.37%			40.82%	1	38.787	52.04%		33.0/%			
Detected/sampling even	nt	35.58%		67	.50%		55.00%	36.	89%		36.63%		32.32%	48.	98%		41.75%		43.3	7%		40.48%			44.88%		55.10%	54.5	9%